Eli Lilly And Co patents expiration
1. Axiron patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8784878 | ELI LILLY AND CO | Transdermal delivery rate control using amorphous pharmaceutical compositions |
Jul, 2023
(2 months ago) | |
| US8993520 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(2 years from now) | |
| US9180194 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(2 years from now) | |
| US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
| US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
| US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
| US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(3 years from now) | |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 23 November, 2010
Treatment: A method of transdermally delivering testosterone; A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of transdermal administration of a physiologic...
Dosage: SOLUTION, METERED;TRANSDERMAL
AXIRON family patents
2. Baqsimi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6938798 | ELI LILLY AND CO | Fluid or powdery product dispensing device |
Jan, 2022
(1 year, 8 months ago) | |
| US10213487 | ELI LILLY AND CO | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(12 years from now) | |
| US10894133 | ELI LILLY AND CO | Device for dispensing a fluid product |
Jan, 2038
(14 years from now) | |
| US10765602 | ELI LILLY AND CO | Medication delivery systems and methods |
Sep, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Jul 24, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 24 July, 2019
Treatment: Treatment of severe hypoglycemia in patients with diabetes
Dosage: POWDER;NASAL
BAQSIMI family patents
3. Mounjaro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(7 years from now) | |
| US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(7 years from now) | |
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 2026-05-13
Market Authorisation Date: 13 May, 2022
Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION;SUBCUTANEOUS
MOUNJARO family patents
4. Olumiant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(5 years from now) | |
| US9737469 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(8 years from now) | |
| US9089574 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(9 years from now) | |
| US11045474 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 31, 2023 |
| New Indication (I) | May 10, 2025 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 2022-05-31
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of rheumatoid arthritis; Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-i...
Dosage: TABLET;ORAL
OLUMIANT family patents
5. Reyvow patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Feb, 2028
(4 years from now) | |
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748459 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 2024-02-01
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET;ORAL
REYVOW family patents
6. Verzenio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7855211 | ELI LILLY AND CO | Protein kinase inhibitors |
Dec, 2029
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Oct 12, 2024 |
| New Indication (I) | Oct 12, 2024 |
Drugs and Companies using ABEMACICLIB ingredient
Market Authorisation Date: 28 September, 2017
Treatment: In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (h...
Dosage: TABLET;ORAL
VERZENIO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic